SCID-beige mouse recipients of human coronary artery grafts (n=9 from 5 artery donors) received 1.5×108 allogeneic human PBMC (from one of 2 PBMC donors) at 1 wk post-op and were treated with IgG or TGF-β antibody at 250 μg s.c., 3x per wk, from 1 to 5 wk post-op. The artery grafts were procured at 5 wk post-op and the abundance of transcripts for (A) TGF-β1, TGF-β2, TGF-β3, (B) CD31, SMA, CD3ε, (C) IL-6, IL-8, and IP-10 normalized to GAPDH were measured by quantitative RT-PCR. *P<0.05, TGF-β Ab or IgG vs. No treatment, +P<0.05, TGF-β Ab vs. IgG, one-way ANOVA.